Calliditas Therapeutics AB (CALT)

NASDAQ: CALT · IEX Real-Time Price · USD
15.17
+1.05 (7.41%)
At close: Sep 29, 2022 4:30 PM
15.58
+0.41 (2.73%)
After-hours: Sep 30, 2022 5:45 PM EDT
7.41%
Market Cap 395.85M
Revenue (ttm) 33.64M
Net Income (ttm) -59.62M
Shares Out 26.10M
EPS (ttm) -2.27
PE Ratio n/a
Forward PE 5.70
Dividend n/a
Ex-Dividend Date n/a
Volume 1,753
Open 14.93
Previous Close 14.12
Day's Range 14.93 - 15.24
52-Week Range 12.55 - 27.50
Beta 1.41
Analysts Buy
Price Target 35.52 (+134.2%)
Earnings Date Aug 18, 2022

About CALT

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary ... [Read more...]

Industry Biotechnology
IPO Date Jun 5, 2020
Employees 137
Stock Exchange NASDAQ
Ticker Symbol CALT
Full Company Profile

Financial Performance

In 2021, CALT's revenue was 229.35 million, an increase of 26,141.08% compared to the previous year's 874,000. Losses were -500.29 million, 15.4% more than in 2020.

Financial numbers in SEK Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for CALT stock is "Buy." The 12-month stock price forecast is 35.52, which is an increase of 134.21% from the latest price.

Price Target
$35.52
(134.21% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Calliditas' partner STADA launches the first medicine authorized in the EU for treating primary IgA nephropathy

STOCKHOLM , Sept. 20, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that its European commercial partner, STADA Arzneimittel AG, ...

1 week ago - PRNewsWire

Calliditas Therapeutics: Interim Report Q2, 2022

STOCKHOLM , Aug. 18, 2022 /PRNewswire/ -- European approval for Kinpeygo® "On May 19th, the European Medicines Agency (EMA) announced that it had adopted a positive opinion regarding the application for...

1 month ago - PRNewsWire

Can Calliditas Therapeutics AB Sponsored ADR (CALT) Climb 160% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 160.3% in Calliditas Therapeutics AB Sponsored ADR (CALT). While the effectiveness of this highly sought-after me...

1 month ago - Zacks Investment Research

Number of shares and votes in Calliditas Therapeutics

STOCKHOLM , July 29, 2022 /PRNewswire/ -- During July, Calliditas Therapeutics AB (publ) has issued 51,399 ordinary shares as part of the company's long-term incentive program for certain members of the...

2 months ago - PRNewsWire

How Much Upside is Left in Calliditas Therapeutics AB Sponsored ADR (CALT)? Wall Street Analysts Think 200%

The consensus price target hints at a 200.3% upside potential for Calliditas Therapeutics AB Sponsored ADR (CALT). While empirical research shows that this sought-after metric is hardly effective, an up...

2 months ago - Zacks Investment Research

Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy ...

Kinpeygo® (developed under the name NEFECON) is the first and only EMA- approved treatment for IgAN Everest Medicines has exclusive rights to develop and commercialize NEFECON in Greater China, Singapor...

2 months ago - PRNewsWire

European Commission approves Kinpeygo® for adults with primary IgA nephropathy

STOCKHOLM , July 15, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the European Commission (EC) has granted conditional mark...

2 months ago - PRNewsWire

Calliditas announces additions to the management team

STOCKHOLM , July 11, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that the company has added two members to its management team...

2 months ago - PRNewsWire

Calliditas Therapeutics establishes a U.S. At-the-Market Program

STOCKHOLM, Sweden , June 28, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas" or "the Company") today announced that it has filed with the U....

3 months ago - PRNewsWire

Issuance and repurchase of C-shares to establish an at-the-market program

STOCKHOLM , June 20, 2022 /PRNewswire/ -- The Board of Directors of Calliditas Therapeutics AB (publ) today resolved to carry out a new issue of 5,908,018 C-shares and to subsequently immediately repurc...

3 months ago - PRNewsWire

Calliditas' Kinpeygo Receives CHMP Backing For Kidney Disease

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional approval for Calliditas Therapeutics AB's (NASDAQ: CALT) Kin...

4 months ago - Benzinga

Calliditas receives positive CHMP opinion in IgA nephropathy

STOCKHOLM , May 19, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Committee for Medicinal Products for Human Use (CHMP) ...

4 months ago - PRNewsWire

Calliditas Therapeutics: Interim Report Q1, 2022

STOCKHOLM , May 18, 2022 /PRNewswire/ -- Start of TARPEYO™ Commercial Launch in the US "During the first quarter Calliditas launched its first commercial product, TARPEYO, in the US, supported by 40 exp...

4 months ago - PRNewsWire

First patient randomized in Phase 2 trial in head and neck cancer

STOCKHOLM , May 17, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the first patient has been randomized in the company's pr...

4 months ago - PRNewsWire

Calliditas Therapeutics Launches an Online Patient Platform

This launch coincides with the inaugural IgAN Awareness Day This launch coincides with the inaugural IgAN Awareness Day

4 months ago - GlobeNewsWire

Calliditas Therapeutics to participate in upcoming investor conferences

STOCKHOLM , May 10, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that its management team will participate in the following upco...

4 months ago - PRNewsWire

Calliditas Therapeutics' 2021 Annual Report Published

STOCKHOLM, April 27, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2021 now is available at the company's website: ww...

5 months ago - PRNewsWire

Notice of annual general meeting of Calliditas Therapeutics AB (publ)

STOCKHOLM , April 14, 2022 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the annual general meeting on...

5 months ago - PRNewsWire

Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2018/2022

STOCKHOLM, March 24, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced today that CEO Renée Aguiar-Lucander has subscribed for 175,0...

6 months ago - PRNewsWire

Calliditas Expects EMA's CHMP Opinion For Nefecon In Q2

Calliditas Therapeutics AB (NASDAQ: CALT) says that the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) can be expected in Q2 of 2022. In its ...

6 months ago - Benzinga

Calliditas provides a regulatory update on EMA process for Nefecon

STOCKHOLM, March 22, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the opinion of the Committee for Medicinal Products for H...

6 months ago - PRNewsWire

Updated regulatory plans for NEFECON in China

STOCKHOLM, March 18, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that partner Everest Medicines (HKEX 1952.HK) plans to submit ...

6 months ago - PRNewsWire

Expansion of Everest Medicine's licence agreement to include South Korea

STOCKHOLM, March 14, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has expanded its licensing agreement with Eve...

6 months ago - PRNewsWire

Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Comm...

Deal signals Company's latest efforts to further enhance its international commercial footprint SHANGHAI, March 13, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company foc...

6 months ago - PRNewsWire

First patient randomized in pivotal TRANSFORM study with setanaxib

STOCKHOLM, Feb. 15, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the first patient has been randomized in the company's piv...

7 months ago - PRNewsWire